BEIJING and PARIS, October 15, 2015 /PRNewswire/ --
SPIREN Ventures, a Commercialization Front Office specialized in healthcare, announces the acquisition of the exclusive rights of a non-invasive technology screening heavy metals in China and India. This technology is comprised of a medical device and a Service as a Software (SaaS) model. It screens heavy metals and mineral deficiencies, and will be marketed under the brand Oligoscan®. Made in Europe, it has been granted the CE mark and ISO 13485 certificate.
Gaëtan de KERROS, Managing Director of SPIREN Ventures, adds: "Recent government initiatives and traditional and social media have raised exceptional awareness around pollution particularly in China and India. This non-invasive and connected technology helps screen heavy metals as well as mineral deficiencies among a large population. It provides a comprehensive report which contributes to achieve a balanced nutrition and healthy life style."
About SPIREN Ventures
SPIREN Ventures is the latest initiative from SPIREN HealthCare. SPIREN Ventures aims at commercializing Pharmaceutical, Medical Device and Digital products and services in China and India. With Medical Device, Pharmaceutical & Consumer Health industry EXPERTISE, EXPERIENCE track records in China, the team manages the whole commercialization. The company was founded in early 2015, is established in Hong Kong, and has offices in Beijing and Paris.
To know more, please visit http://www.spirenhealthcare.com .
SOURCE SPIREN Ventures